RxDoctor Payments Data

Jared Morris, DO

Family Medicine · Layton, UTNPI 1992952287

Payments from drug & device makers

$7,831in general payments, 2019–2025

Across 487 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$576
  • Boehringer Ingelheim$569
  • Astellas Pharma US Inc$518
  • Antares Pharma, Inc.$367
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$356
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$7,71999%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,831 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$61,534
Medicare patients
115
Services billed
1,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$26,209
MounjaroTirzepatide17$17,854
JardianceEmpagliflozin20$16,934
EliquisApixaban16$14,592
TrulicityDulaglutide14$14,396
LinzessLinaclotide20$13,391
JanuviaSitagliptin Phosphate16$11,895
FarxigaDapagliflozin Propanediol15$8,783
Xigduo XrDapaglifloz Propaned/Metformin15$8,494
Janumet XrSitagliptin Phos/Metformin Hcl13$7,069
Testosterone31$6,838
TradjentaLinagliptin12$6,698
SymbicortBudesonide/Formoterol Fumarate18$4,325
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$3,128
Omeprazole125$1,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$576$32,25031 claims
Novo NordiskOzempic$198$26,20927 claims
Boehringer IngelheimJardiance, Tradjenta$569$23,63232 claims
MerckJanuvia, Janumet Xr$120$18,96329 claims
PfizerEliquis$340$14,59216 claims
AbbVieLinzess$1,429$13,39120 claims
AstraZenecaFarxiga, Symbicort$129$13,10933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.

Other family medicine in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →